Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baxter InternationalBAX -2.39%59 EV-to-EBITDA is 25.39 as of Jul. 21, 2026, which is 33% above its 10-year median of 19.08. GuruFocus rates BAX with a GF Score™ of 59/100 and a GF Value™ of $34.41 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Baxter International ranks worse than 74.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Baxter International's enterprise value is $19,041 Mil.
Baxter International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $750 Mil. Therefore, Baxter International's EV-to-EBITDA for today is 25.39.
The historical rank and industry rank for Baxter International's EV-to-EBITDA or its related term are showing as below:
BAX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.57 Med: 19.08 Max: 43.22
Current: 25.39
During the past 13 years, the highest EV-to-EBITDA of Baxter International was 43.22. The lowest was -37.57. And the median was 19.08.
BAX's EV-to-EBITDA is ranked worse than 74.9% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.005
vs BAX: 25.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Baxter International (NYSE:BAX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Baxter International's PE Ratio (TTM) for today is calculated as:
Baxter International's share price for today is $22.07.
Baxter International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Baxter International's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Baxter International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Baxter International's EV-to-EBITDA falls into.
Baxter International's current Enterprise Value is $19,041 Mil.
Baxter International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $750 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International (BAX) has a EV-to-EBITDA of 25.39 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Baxter International. This is 33% above median its historical median of 19.08. According to the industry distribution chart, Baxter International ranks #382 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 74.9%.
Is Baxter International's EV-to-EBITDA too high?
Baxter International's current EV-to-EBITDA of 25.39 is 33% above median its 10-year median of 19.08. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.01. Baxter International's value of 25.39 is 81.3% above this industry median. Based on the distribution chart, Baxter International ranks #382 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Baxter International has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's EV-to-EBITDA compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #382 out of 510 companies for EV-to-EBITDA. This places Baxter International in the lower half of its industry. The industry median EV-to-EBITDA is 14.01. Baxter International's value of 25.39 is 81.3% above this benchmark. While the company's 10-year median is 19.08 vs. the industry median of 14.01, Baxter International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.01, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baxter International's current EV-to-EBITDA of 25.39 is 81.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Baxter International. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current EV-to-EBITDA is 25.39, which is 33% above median its own 10-year median of 19.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (BAX) is currently considered Possible Value Trap. The stock's GF Value™ is $34.41, compared to a current price of $22.07 — trading 35.9% below its estimated fair value. The current EV-to-EBITDA is 25.39, which is 33% above median its 10-year median of 19.08 and 81.3% above the Medical Devices & Instruments industry median of 14.01. Baxter International's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Baxter International (BAX), the current EV-to-EBITDA is 25.39 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of $22.07 is trading 35.9% below its estimated GF Value™ of $34.41.
GuruFocus considers Baxter International to be Possible Value Trap.
Key valuation signals for BAX:
EV-to-EBITDA: 25.39 (33% above median its 10-year median of 19.08)
GF Value™: $34.41 vs. price of $22.07 (35.9% below fair value)
Industry Position: 81.3% above the Medical Devices & Instruments median (#382 of 510)
No single metric tells the full story. See the BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
59GF Score
Get the complete analysis for BAX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BAX has been successfully added to your 
